Bacteria Shown To Cause Blood Clots Bacteria can directly cause human blood and plasma to clot - a process that was previously thought to have been lost during the course of vertebrate evolution, according to new research at the University of Chicago, National Institute of Allergy and Infectious Diseases, and Institut Pasteur in Paris. Their findings were published online Nov. 2 in Nature Chemical Biology.
Source: www.medicalnewstoday.comAvineuro Announced Advancing Potent Small Molecule For Treatment Of Alzheimer's Disease To Clinical Development Avineuro Pharmaceuticals, Inc. announced today the completion of preclinical studies of AVN-101, a potent small molecule for treatment of Alzheimer's disease. These studies demonstrate that AVN-101 is safe and well tolerated, and that it has a favorable pharmacokinetic profile. Based on these and other results, Avineuro Pharmaceuticals, Inc. plans to advance AVN-101 into clinical trials in Q1 2009.
Source: www.medicalnewstoday.comVirtual Reality Helps MS Patients Regain Stability While Walking, Medigait LLC Claims Studies performed over the last few years show many Multiple Sclerosis (MS) patients no longer have to live with a meandering or unsteady gait caused by their disease. According to a study published in the highly acclaimed medical journal "Neurology", closed-loop visual feedback helps MS patients improve their walking.
Source: www.medicalnewstoday.comTreating Osteoporosis After Hip Fracture Most patients who suffer a hip fracture are referred to their primary care physicians for osteoporosis follow-up care. However, according to a study published in the November 2008 issue of The Journal of Bone and Joint Surgery (http://www.ejbjs.
Source: www.medicalnewstoday.comCalifornia Colorectal Cancer Coalition Holds Its First Community Forum To Save Lives By Promoting And Advocating For Colorectal Cancer Screening To prevent more deaths and suffering from the third most common cancer in California, the California Colorectal Cancer Coalition (C4) http://cacoloncancer.org/ recently held its first community forum, calling for a 10 percent increase in the rates of colorectal cancer screening.
Source: www.medicalnewstoday.comHalozyme Therapeutics Begins Phase 2 Clinical Trial Of Insulin With RHuPH20 In Type 1 Diabetic Patients Halozyme Therapeutics, Inc. (Nasdaq: HALO), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix, announced it has started a Phase 2 study of proprietary recombinant human hyaluronidase enzyme (rHuPH20) co-formulations with Humulin(R) R (regular insulin human injection) and with Humalog(R) (insulin lispro) in Type 1 diabetic patients.
Source: www.medicalnewstoday.comPortola Pharmaceuticals Initiates Phase II Trial Of Betrixaban, Its Novel Oral Factor Xa Inhibitor For Stroke Prevention In Atrial Fibrillation Portola Pharmaceuticals, a biopharmaceutical company developing innovative
drugs that provide significant advances in cardiovascular and inflammatory diseases, and cancer, announced that it has begun patient enrollment in a large Phase II clinical trial of betrixaban, the Company's novel oral Factor Xa inhibitor anticoagulant, for stroke prevention in patients with atrial fibrillation (SPAF).
Source: www.medicalnewstoday.comBioMarin Announces Initiation Of Clinical Assessment Program For Morquio A Syndrome BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced the initiation of the Morquio Clinical Assessment Program (MorCAP) for patients with the lysosomal storage disease Mucopolysaccharidosis Type IVA (MPS IVA), or Morquio A Syndrome.
Source: www.medicalnewstoday.comAntiangiogenic Role Of 2ME2 Demonstrated In Rheumatoid Arthritis Models EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, announced the publication of preclinical results for 2ME2 (Panzem(R) or 2- methoxyestradiol) in rheumatoid arthritis (RA). The results of the study, conducted by EntreMed collaborator, Dr.
Source: www.medicalnewstoday.comGlobal Scientific Research Collaboration Leads To Breakthrough In Culturing HEK 293 Cells In Animal-Free Media A recent breakthrough was published in the scientific journal In Vitro Cellular & Developmental Biology showing the benefit of using recombinant lactoferrin (Lacromin) to promote growth of HEK 293 cells using a serum-free and animal-free media. Lactoferrin is a protein derived from colostrum and has been made using recombinant techniques in an animal-free system by InVitria (see Lacromin). HEK 293 cells are used by biotechnology and biopharmaceutical companies to produce human therapeutics.
Source: www.medicalnewstoday.com
# posted by Network @ 5:00 AM
